Drugmakers Saw Robust ROI and Lower Development Costs in 2021, Says Analysis Post author:PacConAdmin Post published:January 12, 2022 Post category:Drug Industry Daily It’s been a banner year for the financial side of the pharmaceutical industry. Source: Drug Industry Daily You Might Also Like FDA Lowers Some BsUFA II Fees for Fiscal 2019 July 30, 2018 Report: Top Drugmakers Put Tax Savings Toward Stock Buybacks Not Lower Prices April 10, 2018 J&J to Drop Emergent After Mutual Claims of Contract Breach June 7, 2022